David Nolan

10.1k total citations · 2 hit papers
149 papers, 7.3k citations indexed

About

David Nolan is a scholar working on Virology, Emergency Medicine and Infectious Diseases. According to data from OpenAlex, David Nolan has authored 149 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Virology, 43 papers in Emergency Medicine and 40 papers in Infectious Diseases. Recurrent topics in David Nolan's work include HIV-related health complications and treatments (43 papers), HIV Research and Treatment (43 papers) and HIV/AIDS drug development and treatment (33 papers). David Nolan is often cited by papers focused on HIV-related health complications and treatments (43 papers), HIV Research and Treatment (43 papers) and HIV/AIDS drug development and treatment (33 papers). David Nolan collaborates with scholars based in Australia, United States and United Kingdom. David Nolan's co-authors include S. Mallal, Ian James, A. Martin, E. McKinnon, Elizabeth J. Phillips, Corey Moore, E. Hammond, Silvana Gaudieri, Campbell S. Witt and Cyril Mamotte and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

David Nolan

139 papers receiving 7.1k citations

Hit Papers

HLA-B*5701 Screening for ... 2002 2026 2010 2018 2008 2002 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. HLA-B*5701 Screening for Hypersensitivity to Abacavir
    2008 1.2k citations S. Mallal, David Nolan et al. profile →
  2. Association between presence of HLA-B*5701, HLA-DR7 , and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir
    2002 1.0k citations S. Mallal, David Nolan et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
David Nolan 2.3k 2.1k 1.9k 1.5k 1.3k 149 7.3k
Yong Huang 307 0.1× 1.8k 0.8× 1.4k 0.7× 853 0.6× 876 0.7× 167 7.2k
Samir K. Gupta 227 0.1× 2.3k 1.1× 909 0.5× 1.7k 1.2× 275 0.2× 186 5.5k
Jean‐Philippe Bastard 268 0.1× 669 0.3× 709 0.4× 1.1k 0.8× 582 0.5× 100 7.0k
Mario Regazzi 430 0.2× 869 0.4× 415 0.2× 148 0.1× 311 0.2× 136 3.6k
Judy K. Shigenaga 185 0.1× 544 0.3× 353 0.2× 646 0.4× 1.1k 0.9× 65 5.8k
Cristóbal Richart 282 0.1× 413 0.2× 361 0.2× 321 0.2× 746 0.6× 216 6.5k
William Lewis 96 0.0× 1.9k 0.9× 1.2k 0.6× 1.8k 1.2× 277 0.2× 111 6.8k
Cyril Mamotte 676 0.3× 302 0.1× 225 0.1× 131 0.1× 404 0.3× 67 3.4k
Lorraine C. Racusen 198 0.1× 633 0.3× 135 0.1× 359 0.2× 1.5k 1.2× 160 9.5k
Michael D. Roth 1.5k 0.6× 325 0.2× 291 0.2× 74 0.1× 2.2k 1.8× 125 6.9k

Countries citing papers authored by David Nolan

Since Specialization
Citations

This map shows the geographic impact of David Nolan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Nolan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Nolan more than expected).

Fields of papers citing papers by David Nolan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Nolan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Nolan. The network helps show where David Nolan may publish in the future.

Co-authorship network of co-authors of David Nolan

This figure shows the co-authorship network connecting the top 25 collaborators of David Nolan. A scholar is included among the top collaborators of David Nolan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Nolan. David Nolan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
McLean‐Tooke, Andrew, et al.. (2025). VEXAS: A review of current understandings and emerging treatment strategies. Frontiers in Immunology. 16. 1644404–1644404.
2.
Lee, Silvia, Alison Castley, Matthew Knuiman, et al.. (2025). Inflammatory and vascular biomarkers as predictors of all‐cause death and cardiovascular outcomes in an Australian community‐based cohort. Physiological Reports. 13(11). e70379–e70379. 1 indexed citations
3.
Rogerson, David, et al.. (2024). Deloading Practices in Strength and Physique Sports: A Cross-sectional Survey. Sports Medicine - Open. 10(1). 26–26.
4.
Strafford, Ben William, et al.. (2023). Integrating Deloading into Strength and Physique Sports Training Programmes: An International Delphi Consensus Approach. Sports Medicine - Open. 9(1). 87–87. 5 indexed citations
5.
6.
Nolan, David, et al.. (2023). Physical Match Demands of International Women’s Rugby Union: A Three-Year Longitudinal Analysis of a Team Competing in The Women’s Six Nations Championship. Journal of Functional Morphology and Kinesiology. 8(1). 32–32. 7 indexed citations
7.
Lee, Silvia, Alison Castley, Mark Divitini, et al.. (2022). Long-Term Associations between Human Cytomegalovirus Antibody Levels with All-Cause Mortality and Cardiovascular Outcomes in an Australian Community-Based Cohort. Viruses. 14(12). 2676–2676. 2 indexed citations
8.
Santis, Dianne De, Erika Della Mina, Sam Salman, et al.. (2022). A Novel Targeted Amplicon Next-Generation Sequencing Gene Panel for the Diagnosis of Common Variable Immunodeficiency Has a High Diagnostic Yield. Journal of Molecular Diagnostics. 24(6). 586–599. 6 indexed citations
9.
10.
Nolan, David, et al.. (2019). Are there differences in lifting technique between those with and without low back pain? A systematic review. Scandinavian Journal of Pain. 20(2). 215–227. 41 indexed citations
11.
Castley, Alison, Shailendra Sawleshwarkar, Rick Varma, et al.. (2017). A national study of the molecular epidemiology of HIV-1 in Australia 2005–2012. PLoS ONE. 12(5). e0170601–e0170601. 21 indexed citations
12.
Jones, Anderson P., Stephanie Trend, Scott N. Byrne, et al.. (2017). Altered regulatory T‐cell fractions and Helios expression in clinically isolated syndrome: clues to the development of multiple sclerosis. Clinical & Translational Immunology. 6(5). e143–e143. 23 indexed citations
13.
Castley, Alison, et al.. (2015). Longitudinal Trends in Western Australian HIV-1 Sequence Diversity and Viral Transmission Networks and Their Influence on Clinical Parameters: 2000–2014. AIDS Research and Human Retroviruses. 32(3). 211–219. 5 indexed citations
14.
Herrmann, S., E. McKinnon, Christophe Lalanne, et al.. (2013). HIV-related stigma and physical symptoms have a persistent influence on health-related quality of life in Australians with HIV infection. Health and Quality of Life Outcomes. 11(1). 56–56. 74 indexed citations
15.
Kostenko, Lyudmila, Anthony W. Purcell, Nicholas A. Williamson, et al.. (2008). Human Leukocyte Antigen Class I-Restricted Activation of CD8+ T Cells Provides the Immunogenetic Basis of a Systemic Drug Hypersensitivity. Immunity. 28(6). 822–832. 248 indexed citations
16.
Kostenko, Lyudmila, Anthony W. Purcell, Nicholas A. Williamson, et al.. (2008). Human Leukocyte Antigen Class I-Restricted Activation of CD8+ T Cells Provides the Immunogenetic Basis of a Systemic Drug Hypersensitivity. Immunity. 29(1). 165–165. 1 indexed citations
17.
Nolan, David, Peter Reiss, & S. Mallal. (2005). Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. Expert Opinion on Drug Safety. 4(2). 201–218. 30 indexed citations
18.
Nolan, David & S. Mallal. (2003). Thymidine analogue-sparing highly active antiretroviral therapy (HAART).. PubMed. 8(1). 2–6. 10 indexed citations
19.
Nolan, David, Silvana Gaudieri, & S. Mallal. (2003). Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity?. PubMed. 8(2). 36–41. 38 indexed citations
20.
Cherry, Catherine L., David Nolan, S. Mallal, et al.. (2003). Longitudinal associations between antiretroviral treatments and quantification of tissue mitochondrial DNA from ambulatory subjects with HIV infection. Murdoch Research Repository (Murdoch University). 23. 73–5. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yong Huang Breakdown of academic impact, for papers by Samir K. Gupta Breakdown of academic impact, for papers by Jean‐Philippe Bastard Breakdown of academic impact, for papers by Mario Regazzi Breakdown of academic impact, for papers by Judy K. Shigenaga Breakdown of academic impact, for papers by Cristóbal Richart Breakdown of academic impact, for papers by William Lewis Breakdown of academic impact, for papers by Cyril Mamotte Breakdown of academic impact, for papers by Lorraine C. Racusen Breakdown of academic impact, for papers by Michael D. Roth
Rankless by CCL
2026